Elegen is blazing a path towards a biology-based economy with a highly innovative approach to DNA synthesis that delivers an industry leading length of 7kb in 7 business days with a 99.999% per base accuracy. Our multidisciplinary team of best-in-class biologists, chemists, hardware, and software engineers apply cutting-edge technologies and methods to solve critical bottlenecks in synthetic biology workflows to help our customers in pharma, biotech, agbio, and biomanufacturing streamline their work and realize the full potential of programmable biology.
Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is well-capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve, and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success. Over eight years in his previous role as VP of R&D at a leading molecular diagnostics company, he co-invented and launched five precision molecular diagnostic products, including a best-in-class noninvasive prenatal test used by millions. These products earn more than $350 million per year in revenue and enabled an IPO.
Elegen is an Equal Opportunity Employer.
Elegen provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, genetic characteristics, or any other category protected by law. All applicants have rights under the following Federal Employment Laws:
